Male breast cancer masquerading as a chronic chest wall ulcer
DOI:
https://doi.org/10.18203/2349-2902.isj20263867Keywords:
Male breast cancer, Invasive breast carcinoma, Chest wall ulcer, Diagnostic challenge, GATA3, Estrogen receptor, Progesterone receptor, HER2Abstract
Male breast cancer is rare and may present with atypical local findings, resulting in delayed or incorrect initial diagnostic consideration. A large ulcerative lesion involving the male chest wall may mimic a primary cutaneous malignancy or chronic inflammatory/infective ulcer. A 49-year-old man presented with a large ulceroproliferative lesion involving the left anterior chest wall and nipple–areolar region. The lesion measured approximately 23×75×62 mm³ on imaging and was associated with left axillary lymphadenopathy. Ultrasonography demonstrated a heterogeneous hypoechoic vascular mass, while contrast-enhanced CT showed an ulcerated soft-tissue lesion involving the skin and abutting/involving the underlying pectoral musculature. Core biopsy showed poorly differentiated carcinoma. Immunohistochemistry demonstrated CK7 positivity, strong GATA3 positivity, diffuse strong estrogen receptor and progesterone receptor expression (Allred score 8/8 for both), and HER2 negativity, supporting mammary origin. The patient underwent wide local excision with left axillary lymph node dissection and reconstruction with a latissimus dorsi myocutaneous flap. Final pathology showed a 10×7×2 cm³ infiltrative invasive breast carcinoma involving skin and skeletal muscle, with lymphovascular and perineural invasion, clear margins, and metastases in 3 of 10 axillary lymph nodes with extranodal extension. Male breast carcinoma should be considered in the differential diagnosis of persistent or fungating ulcers involving the nipple–areolar or anterior chest wall region. Correlation of clinical findings, imaging, histopathology and immunohistochemistry is essential for establishing the primary site and guiding treatment.
References
Fox S, Speirs V, Shaaban AM. Male breast cancer: an update. Virchows Arch. 2022;480(1):85-93.
Khan NAJ, Tirona M. An updated review of epidemiology, risk factors, and management of male breast cancer. Med Oncol. 2021;38:39.
Yalaza M, İnan A, Bozer M. Male breast cancer. J Breast Health. 2016;12(1):1-8.
Giordano SH. Breast cancer in men. N Engl J Med. 2018;378(24):2311-20.
WHO Classification of Tumours Editorial Board. Breast Tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2019.
National Cancer Institute. Breast Cancer Treatment (PDQ®): Health Professional Version. TNM breast cancer staging definitions. Bethesda, MD: NCI. Available at: https://www.cancer.gov/types/ breast/hp/breast-treatment-pdq. Accesed on 5 June 2026.
Hassett MJ, Somerfield MR, Baker ER, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol. 2020;38(16):1849-63.
Zheng G, Leone JP. Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment. Int J Breast Cancer. 2022;2022:1734049.
McClurg DP, Urquhart G, McGoldrick T, et al. Analysis of the clinical advancements for BRCA-related malignancies highlights the lack of treatment evidence for BRCA-positive male breast cancer. Cancers (Basel). 2022;14(13):3175.
Johnson AE, Coopey SB, Spring LM, et al. Management and outcomes of men diagnosed with primary breast cancer. Breast Cancer Res Treat. 2021;188(3):561-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Pooja P. Patel, Arpit Bandi, V. C. Geetha Krishna

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.